Kulier A, Gombotz H, Stubenvoll E
Department of Anesthesiology, University of Graz, Austria.
Clin Investig. 1994;72(6 Suppl):S19-24.
Recombinant human erythropoietin (rHuEPO) has proved to be a useful drug that can aid in protecting patients from possible hazards of homologous blood. Use of rHuEPO for patients scheduled for coronary artery bypass graft (CABG) surgery can enhance the benefit of a preoperative autologous blood donation program while simultaneously minimizing its risks. The main objective are to decrease homologous transfusion requirements by increasing the amount of collected autologous blood and to maximize safety by ameliorating a pre- or postoperative anemia. The goal of this review is to assess the possible benefits of perioperative use of rHuEPO during CABG surgery. Furthermore, we evaluate its ability to augment the quality of collected blood and to lower the risk of autologous blood donation. Side effects, dosages, manner of administration, concomitant iron therapy and suggestions for special patient groups will be discussed.
重组人促红细胞生成素（rHuEPO）已被证明是一种有用的药物，可帮助保护患者免受同源血可能带来的危害。对于计划进行冠状动脉搭桥术（CABG）的患者，使用rHuEPO可以提高术前自体献血计划的益处，同时将其风险降至最低。主要目标是通过增加自体血采集量来减少同源输血需求，并通过改善术前或术后贫血来最大化安全性。本综述的目的是评估CABG手术围手术期使用rHuEPO的潜在益处。此外，我们评估其提高采集血液质量和降低自体献血风险的能力。还将讨论副作用、剂量、给药方式、伴随的铁剂治疗以及针对特殊患者群体的建议。
